NCT04013854View on ClinicalTrials.gov

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Melanoma Stage IIIMelanoma
Interventions
DRUG

nivolumab

All arms will receive a pre-surgery dose of nivolumab (480 mg IV). Post-surgery nivolumab doses will be determined by pathologic response and randomization.

DRUG

Ipilimumab

Only subjects who fail to achieve a complete, or near complete, pathological response, and are then randomized to Arm C will receive Ipilimumab (1 mg/kg) )

Trial Locations (3)

17601

Lancaster General Hospital, Lancaster

19104

Abramson Cancer Center, University of Pennsylvania, Philadelphia

27710

Duke Cancer Institute, Durham

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT04013854 - Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | Biotech Hunter | Biotech Hunter